Marcadores tumorales en cáncer de mama. Revisión sistemática

Abstract

BACKGROUND: Breast cancer is the most frequent malignant tumor in women around the world. The FDA-approved tumor markers are cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA), and are frequently used for the detection and control of breast cancer. OBJECTIVE: To present the current available information on the usefulness of tumor markers CA 15-3 and carcinoembryonic antigen in the detection of metastases and their prognostic value in breast cancer. METHODOLOGY: A systematic search of publications in English in the Medline- PubMed database was performed, using the terms: “biomarkers”, “tumor”, “tumor biomarkers”, “marker”, “tumor marker”, “breast neoplasms “,” breast “,” neoplasms “,” cancer “,” mucin-1 “,” ca 15 3 “,” carcinoembryonic antigen “. Original articles, clinical trials, reviews, systematic reviews and meta-analyzes, published between March 28, 2015 and March 25, 2020, were selected to determine the usefulness of the CA 15-3 antigen and carcinoembryonic antigen in breast cancer. RESULTS: Eleven publications that were relevant to determine the usefulness of tumor markers in breast cancer were selected for the writing of this article. CONCLUSIONS: The utility of tumor markers Antigen 15-3 and carcinoembryonic antigen is contradictory, and not fully accepted by oncology associations and inter-national guidelines, however there is evidence that confirms their utility as diagnostic and prognostic markers in breast cancer.